BioSpace News Archive

Data to be Presented at the 2021 Annual Meeting of the American Society for Clinical Oncology

AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced results from the OlympiA Phase III trial showed LYNPARZA®

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA

Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus 30 mg octreotide LAR to 60 mg of octreotide LAR in patients with midgut neuroendocrine tumors

Alkermes plc announced that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 10:30 a.m. ET.

Foresight Diagnostics announced today that two abstracts that report the clinical performance of its minimal residual disease (MRD) detection platform in diffuse large B-cell lymphoma (DLBCL) and non-small cell lung cancer (NSCLC) were chosen for presentation at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8, 2021.

Purdue Pharma L.P. announced that the United States Bankruptcy Court for the Southern District of New York has approved, among other things, the adequacy of Purdue’s disclosure statement filed in connection with its chapter 11 plan of reorganization.

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced positive two-year results from the Tack Optimized Balloon Angioplasty (TOBA) II below-the-knee (BTK) clinical trial.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced that the Company’s 2021 Annual Meeting of Stockholders, scheduled to be held on Thursday, June 3, 2021 at 3:00 p.m., was adjourned to Tuesday, June 29, 2021 at 11:00 a.m.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), and KYE Pharmaceuticals Inc. (“KYE”), today announced a positive decision in their lawsuit in Canadian Federal Court challenging Health Canada’s approval of Medunik’s New Drug Submission (NDS) for Ruzurgi®.